Featured Publications
Broad immune activation underlies shared set point signatures for vaccine responsiveness in healthy individuals and disease activity in patients with lupus
Kotliarov Y, Sparks R, Martins A, Mulè M, Lu Y, Goswami M, Kardava L, Banchereau R, Pascual V, Biancotto A, Chen J, Schwartzberg P, Bansal N, Liu C, Cheung F, Moir S, Tsang J. Broad immune activation underlies shared set point signatures for vaccine responsiveness in healthy individuals and disease activity in patients with lupus. Nature Medicine 2020, 26: 618-629. PMID: 32094927, PMCID: PMC8392163, DOI: 10.1038/s41591-020-0769-8.Peer-Reviewed Original ResearchMeSH KeywordsAdaptive ImmunityAdolescentAdultAgedAged, 80 and overAntibody FormationB-LymphocytesChildChild, PreschoolCohort StudiesFemaleGene Expression ProfilingHumansInfluenza VaccinesInfluenza, HumanLupus Erythematosus, SystemicMaleMiddle AgedTranscriptomeVaccinationYellow FeverYellow Fever VaccineYoung AdultConceptsDisease activityVaccine responsivenessAutoimmune disease activityBlood transcriptional signaturesYellow fever vaccinationSystemic lupus erythematosusClinical quiescenceFever vaccinationLupus erythematosusCancer immunotherapyBaseline predictorsDisease outcomeHealthy subjectsImmune responseI IFNHealthy individualsVaccinationTranscriptional signatureImmune variationBaseline statePatientsExtent of activationBiological basisSurface proteinsInfection response
2021
An immune-based biomarker signature is associated with mortality in COVID-19 patients
Abers MS, Delmonte OM, Ricotta EE, Fintzi J, Fink DL, de Jesus AAA, Zarember KA, Alehashemi S, Oikonomou V, Desai JV, Canna SW, Shakoory B, Dobbs K, Imberti L, Sottini A, Quiros-Roldan E, Castelli F, Rossi C, Brugnoni D, Biondi A, Bettini LR, D’Angio’ M, Bonfanti P, Castagnoli R, Montagna D, Licari A, Marseglia GL, Gliniewicz EF, Shaw E, Kahle DE, Rastegar AT, Stack M, Myint-Hpu K, Levinson SL, DiNubile MJ, Chertow DW, Burbelo PD, Cohen JI, Calvo KR, Tsang JS, Consortium N, Su HC, Gallin JI, Kuhns DB, Goldbach-Mansky R, Lionakis MS, Notarangelo LD. An immune-based biomarker signature is associated with mortality in COVID-19 patients. JCI Insight 2021, 6: e144455. PMID: 33232303, PMCID: PMC7821609, DOI: 10.1172/jci.insight.144455.Peer-Reviewed Original ResearchMeSH KeywordsAdrenal Cortex HormonesAdultAgedAnti-Bacterial AgentsAntibodies, Monoclonal, HumanizedAntiviral AgentsAzithromycinBiomarkersCalgranulin BCase-Control StudiesChemokine CCL2Chemokine CXCL9COVID-19Enzyme InhibitorsFemaleFerritinsGene Expression ProfilingHumansHydroxychloroquineImmunologic FactorsInterferon Type IInterferon-gammaInterleukin-1 Receptor-Like 1 ProteinInterleukin-10Interleukin-15Interleukin-2Interleukin-6LactoferrinLipocalin-2MaleMatrix Metalloproteinase 9Middle AgedMultivariate AnalysisNF-kappa BPrognosisReceptors, Tumor Necrosis Factor, Type ISARS-CoV-2Severity of Illness IndexVascular Endothelial Growth Factor Receptor-1ConceptsType I IFNI IFNSevere acute respiratory syndrome coronavirus 2Whole blood transcriptional signaturesAcute respiratory syndrome coronavirus 2Respiratory syndrome coronavirus 2Immune-based biomarkersCOVID-19 patientsSyndrome coronavirus 2Eventual disease outcomeTissue-resident cellsCoronavirus disease 2019COVID-19Type II IFNInflammatory signatureIL-10Clinical outcomesMultivariable analysisIL-15Aforementioned biomarkersCell subsetsCoronavirus 2IL-1αSoluble biomarkersInflammatory response
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply